Inhibitory effects of uterine endometrial carcinogenesis in Donryu rats by tamoxifen

Cancer Letters

Volumn 134, Issue 1, 1998, Pages 43-51

  Yoshida, Midori ^a   Kudoh, Kayoko ^a   Katsuda, Shin Ichi ^a   Takahashi, Masakazu ^a   Ando, Jin ^a   Maekawa, Akihiko ^a  

^a SASAKI INSTITUTE   (Japan)

Author keywords

Anti estrogen; Carcinogenesis; Rat; Tamoxifen; Uterus

Indexed keywords

ANTIESTROGEN; ESTROGEN; ETHYLNITRONITROSOGUANIDINE; TAMOXIFEN;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ESTROGEN BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENAL GLANDS; ANIMALS; ANTICARCINOGENIC AGENTS; BODY WEIGHT; CARCINOGENICITY TESTS; ENDOMETRIAL NEOPLASMS; ESTRADIOL; FEMALE; GONADS; LIVER; METHYLNITRONITROSOGUANIDINE; ORGAN SIZE; PITUITARY GLAND; PROGESTERONE; RATS; RATS, INBRED STRAINS; TAMOXIFEN; UTERUS;

EID: 0032431063     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00240-7     Document Type: Article

References (39)

1. Ando-Lu J., Takahashi M., Imai S., Ishihara R., Kitamura T., Iijima T., Takano S., Nishiyama K., Sasahara K., Suzuki K., Maekawa A. High-yield induction of uterine endometrial adenocarcinomas in Donryu rats by a single intra-uterine administration of N-ethyl-N′-nitro-N-nitrosoguanidine via the vagina. Jpn. J. Cancer Res. 85:1994;789-793.
2. Bedford G.R., Richardson D.N. Preparation and identification of cis and trans isomers of a substituted triphenylethylene. Nature. 212:1966;733-734.
3. Berthou F., Dreano Y. High-performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolite. J. Chromatol. 616:1993;117-127.
4. Branham W.S., Sheehan D.M., Zehr D.R., Medlock K.L., Nelson C.J., Ridlon E. Inhibition of rat uterine gland genesis by tamoxifen. Endocrinology. 117:1985;2238-2248.
5. Carthew P., Martin E.A., White I.N.H., De Matteis F., Edwards R.E., Dorman B.M., Heydon R.T., Smith L.L. Tamoxifen induces short-term cumulative DNA damage and liver tumor in rats: promotion by phenobarbital. Cancer Res. 55:1995;544-547.
6. Carthew P., Edwards R.E., Nolan B.M., Martin E.A., Smith L.L. Tamoxifen associated uterine pathology in rodents: relevance to women. Carcinogenesis. 17:1996;1577-1582.
7. Chamness G.C., Bannayen G.A., Landry L.A. Jr., Sheridan P.J., McGuire W.L. Abnormal reproductive development in rats after neonatally administered antioestrogen (tamoxifen). Biol. Reprod. 21:1979;1087-1090.
8. Cohen I., Altaras M.M., Lew S., Tepper R., Beyth Y., Ben-Baruch G. Case report. Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature. Gynecol. Oncol. 55:1994;443-447.
9. Cole M.P., Jones C.T.A., Todd I.D.H. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46.474. Br. J. Cancer. 25:1971;270-275.
10. Furr B.J.A., Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25:1984;127-205.
11. Furuya Y., Kohno N., Fujiwara Y., Saitoh Y. Mechanisms of estrogen action on the proliferation of MCF-7 human breast cancer cells in an improved culture medium. Cancer Res. 49:1989;6670-6674.
12. Greaves P., Goonetilleke R., Nunn G., Topham J., Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53:1993;3919-3924.
13. Hard G.C., Iatropoulos M.J., Jordan K., Radi L., Kaltenberg O.P., Imondi A.R., Williams G.M. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifen and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53:1993;4534-4541.
14. Harper M.J.K., Walpole A.L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature. 212:1966;87.
15. Hirsimaki P., Hirsimaki Y., Nieminen L., Payne B.J. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch. Toxicol. 67:1993;49-54.
16. IARC, Tamoxifen, in: IARC Monographs on the Evaluation of Carcinogenic Risks on Humans: Some Pharmacological Drugs, Vol. 66, IARC, Lyon, 1996, pp. 253-365.
17. Jordan V.C. Overview from the international conference on long-term tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. 84:1992;231-234.
18. Kalu D.N., Salerno E., Liu C.C., Echon R., Ray M., Garzazapta M., Hollis B.W. A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner. 15:1991;109-123.
19. Killackey M.A., Hakes T.B., Pierce V.K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep. 69:1985;237-238.
20. Langan-Fahey S.M., Tormey D.C., Jordan V.C. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer. 26:1990;883-888.
21. Li D., Dragan Y., Jordan V.C., Wang M., Pitot H.C. Effects of chronic administration of tamoxifen and toremifen on DNA adducts in the rat liver, kidney and uterus. Cancer Res. 57:1997;1438-1441.
22. Lim K.C., Yaun Z., Lamb J.H., White I.N.H., De Matteis F., Smith L.L. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis. 15:1994;589-593.
23. Maekawa A., Onodera H., Tanigawa H., Furuta K., Matsuoka C., Ogiu T., Hayashi Y. Spontaneous neoplastic and non-neoplastic lesions in aging Donryu rats. Jpn. J. Cancer Res. 77:1986;882-890.
24. Marshall E. Tamoxifen: hanging in the balance. Science. 364:1994;1524-1527.
25. Medlock K.L., Branham W.S., Sheehan D.M. Effect of toremifene on neonatal uterine growth and differentiation. Biol. Reprod. 56:1997;1239-1244.
26. Nagaoka T., Onodera H., Matsushima Y., Todate A., Shibutani M., Ogasawara H., Maekawa A. Spontaneous uterine adenocarcinomas in aged rats and their relation to endocrine imbalance. J. Cancer Res. Clin. Oncol. 116:1990;623-628.
27. Nagaoka T., Takeuchi M., Onodera H., Matsushima Y., Ando-Lu J., Maekawa A. Sequential observation of spontaneous endometrial adenocarcinoma development in Donryu rats. Toxicol. Pathol. 22:1994;261-269.
28. Newbold R.R., Jefferson W.N., Padilla-Burgos E., Bullock B.C. Uterine carcinoma in mice treated neonatally with tamoxifen. Carcinogenesis. 18:1997;2293-2298.
29. Niwa K., Morishita S., Hashimoto M., Itoh T., Fujimoto J., Mori H., Tamaya T. Effects of tamoxifen on endometrial carcinogenesis in mice. Jpn. J. Cancer Res. 89:1998;502-509.
30. Onodera H., Matsushima Y., Mitsumori K., Maekawa A. Supplementary study of phenylbutazone promoting effects using wide organ spectrum two-stage carcinogenesis models in rats. J. Toxicol. Pathol. 6:1993;175-180.
31. Pasqualini J.R., Sumida C., Giambiagi N. Pharmacodynamic and biological effects of anti-estrogens in different models. J. Steroid. Biochem. 31:1988;613-643.
32. Pathak D.N., Pongracz K., Bodell W.J. Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Carcinogenesis. 17:1996;1785-1790.
33. Pathak D.N., Bodell W.J. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis. 15:1994;529-532.
34. M.J. Tucker, H.K. Adam, J.S. Patterson, Tamoxifen, in: D.R. Laurence, A.E. McLean, M. Weatherall (Eds.), Safety Testing of New Drugs, Academic Press, New York, 1984, pp. 125-162.
35. Ueo H., Matsuoka H., Honda M., Inoue H., Takaki R., Akiyoshi T. Chemopreventive effects of tamoxifen in ethyl methanesulphonate-induced rat mammary carcinogenesis. Cancer Lett. 71:1993;19-24.
36. Valavaara R., Kangas L. The significance of estrogen receptors in tamoxifen and toremifene therapy. Ann. Clin. Res. 20:1988;380-388.
37. Williams G.M., Iatropoulos M.J., Djordjevic M.V., Kaltenberg O.P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 14:1993;315-317.
38. Zimniski S.J., Warren R.C. Induction of tamoxifen-dependent rat mammary tumors. Cancer Res. 53:1993;2937-2939.
39. H. Wiseman, Receptor-mediated mechanisms of anticancer action of tamoxifen, in: Tamoxifen, Wiley, New York, 1994, pp. 61-82.